Sponsor: Leo PI: KWD Phase: 2
Tralokinumab monotherapy for moderate to severe atopic dermatitis: LP0162-1326
August 2017- Present
Sponsor: Regeneron PI: SAF Phase: 2
A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Dupilumab Monotherapy In Patients ≥12 To <18 Years Of Age, With Moderate-To-Severe Atopic Dermatitis: R668-AD-1526
August 2017-Present
Sponsor: Regeneron PI: SAF Phase: 1
An Open-Label, Randomized, Actual Use Study of Dupilumab Auto-Injector Device in Patients with Atopic Dermatitis- R668-AD-1607
May 2017- Present
Sponsor: GSK PI: SAF Phase: 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects with Moderate to Severe Atopic Dermatitis- 205050
November 2016- Present
Sponsor: Incyte PI: KWD Phase: 2
A Phase II, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream- Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults with Atopic Dermatitis.- INCB18424-206
April 2017- Present
Sponsor: GlaxosmithKline PI: SAF Phase: 2A
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects with Moderate to Severe Atopic Dermatitis. GSK205050
April 2017- Present
Sponser: Pfizer PI: SAF Phase: 2B
A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Parallel, Multicenter, Dose-Ranging, Study to Evaluate the Efficacy and Safety Profile of PF-04965842 in subjects with Moderate to Severe Atopic Dermatitis.- B7451006
April 2016- May 2017
Sponsor: GlaxoSmithKline PI: SAF Phase: 2
A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis – 203121
February 2016 to March 2017
Sponsor: MedImmune, Limited PI: SAF Phase: 2A
A Phase IIa, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis – D5240C00001
August 2015 to September 2016
Sponsor: Regeneron Pharmaceuticals, Inc. PI: SAF Phase: 3
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis – R668-AD-1415
July 2015 to February 2017
Sponsor: Regeneron Pharmaceuticals, Inc. PI: SAF Phase: 3
An Open-Label Study of Dupilumab in Patients with Atopic Dermatitis Who Participated In Previous Dupilumab Clinical Trials – R668-AD-1225
June 2015 to September 2017
Sponsor: Regeneron Pharmaceuticals PI: SAF Phase: 3
A Phase III Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis – R668-AD-1334
February 2015 to June 2016
Sponsor: Regeneron Pharmaceuticals, Inc. PI: Phase: 2
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis Treated with Dupilumab – R668-AD-1314
September 2014 to December 2015
Sponsor: Anacor Pharmaceuticals, Inc. PI: Phase: 3
A Multicenter, Open-Label Study of the Long-Term Safety of AN2728 Topical Ointment, 2% in the Treatment of Children and Adolescents (Ages 2–17 Years) With Atopic Dermatitis – AN2728-AD-303
February 2014 – November 2015
Sponsor: Anacor Pharmaceuticals, Inc. PI: Phase: 3
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis – AN2728-AD-302
February 2014 – August 2015
Sponsor: Chugai Pharmaceutical Co., Ltd. PI: SAF Phase: 2
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of CIM331 in Atopic Dermatitis Patients Who Are Inadequately Controlled or Intolerant to Topical Therapy – CIM003JG
November 2013 to October 2016
Sponsor: Anacor Pharmaceuticals, Inc. PI: Phase:
An Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN2728 Ointment in Adolescents with Atopic Dermatitis – AN2728-AD-203
May 2012 to November January 2013
Sponsor: Novartis PI: Phase: 1
A first-in-human Study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple topical administrations of BPR277 in patients with atopic dermatitis and Netherton syndrome – CBPR277X2101
October 2011 to February 2013
Sponsor: Astellas Pharma Inc PI: KWD Phase:
APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis – FHI-03-0-161/FG-506-06-37
June 2010 to October 2012
Sponsor: Novartis PI: Phase:
A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Pimecrolimus 1% Cream (PEER Registry)
March 2010 to December 2012
Sponsor: Taro Pharmaceuticals USA, Inc./Novum PI: Phase:
A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Clinical Study to Evaluate the Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Moderate to Severe Atopic Dermatitis – TACR-0707
November 2008 to August 2009
Sponsor: Ceragenix PI: Phase:
A Prospective, Randomized, Investigator-Blind, Controlled, Pilot Study Comparing The Effect of the EpiCeram Device versus Conservative Standard of Care Therapy Utilizing Mid-Strength Topical Steroid XXXXX in the Treatment of Atopic Dermatitis in Pediatric Subjects
November 2006 to May 2007